CRBP Stock Analysis: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$9.46
-0.71 (-6.98%)
âŧ
5d:
+6.05%
30d:
-2.27%
90d:
-13.69%
WAIT
LOW Confidence
Analysis Updated: Aug 10, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $9.46, which is considered slightly high relative to its 30-day fair value range of $8.89 to $9.55.
Technical Outlook: Technically, CRBP is in a downtrend. Immediate support is located at $8.62, while resistance sits at $10.25. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: CRBP scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.60 (+265.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRBP is in a downtrend. Immediate support is located at $8.62, while resistance sits at $10.25. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: CRBP scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.60 (+265.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.89 -
$9.55
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BULLISH: Trading 265.8% below Wall St target ($34.60)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.89 -
$9.55
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$1.50
(15.9%)
Support & Resistance Levels
Support Level
$8.62
Resistance Level
$10.25
Current Trend
Downtrend
Technical data as of
Aug 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.90
Wall Street Target
$34.60
(+265.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 10, 2026 7:16 PM ET
Data refreshes hourly during market hours. Next update: 8:16 PM
Data refreshes hourly during market hours. Next update: 8:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 56 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 51 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 57 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 59 HOLD |
